{"id":"bopv-three-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine-derived poliovirus (VDPV) shedding"},{"rate":null,"effect":"Mild gastrointestinal symptoms"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"bOPV is a live attenuated vaccine containing weakened strains of poliovirus types 1 and 3. When administered orally, it replicates in the intestinal tract and triggers both mucosal and systemic immune responses, inducing the production of neutralizing antibodies and cellular immunity against these poliovirus serotypes. This protects vaccinated individuals from infection and disease caused by wild-type poliovirus.","oneSentence":"bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:33.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus types 1 and 3"}]},"trialDetails":[{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT03581734","phase":"PHASE3","title":"Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-01","conditions":"Vaccine Reaction","enrollment":579},{"nctId":"NCT04576910","phase":"PHASE4","title":"Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2020-11-05","conditions":"Polio, Vaccine Reaction","enrollment":387},{"nctId":"NCT02766816","phase":"PHASE3","title":"A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals","status":"COMPLETED","sponsor":"Bilthoven Biologicals","startDate":"2016-06-08","conditions":"Immune Response to Oral Polio Vaccine","enrollment":1120},{"nctId":"NCT02412514","phase":"PHASE4","title":"Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":456},{"nctId":"NCT01841671","phase":"PHASE4","title":"Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine","status":"UNKNOWN","sponsor":"University of Chile","startDate":"2013-04","conditions":"Polio","enrollment":570},{"nctId":"NCT01633216","phase":"PHASE4","title":"Poliovirus Vaccine Trial in Bangladesh","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2012-05","conditions":"Healthy Infants","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"bOPV (three dose)","genericName":"bOPV (three dose)","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis. Used for Prevention of poliomyelitis caused by poliovirus types 1 and 3.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}